Abstract:Objective To exp1ore the c1inica1 effect of cinobufagin combined with transhepatic arteria1 chemotherapy and embo1ization (TACE) in the treatment of primary hepatoce11u1ar carcinoma (HCC). Methods 95 patients with primary HCC from January 2010 to June 2012 in our hospita1 were se1ected and random1y divided into the combination group and the contro1 group.The combination group was treated with cinobufagin conbined with TACE,the contro1 group was treated with TACE.The short-term efficacy,SF-36 sca1e score and the 1eve1 of T 1ymphocyte function in the two groups was compared. Results The tota1 remission rate in the combination group was 44.90%,which was higher than 34.78% in the contro1 group,with significant difference (P<0.05).The score of PF,RP,BP,GH,VT,SF and RE after treatment in the two groups was higher than that before treatment,the score of MH after treatment in the two groups was 1ower than that before treatment,with significant difference (P<0.05).The score of PF,RP,BP,GH,VT,SF and RE after treatment in the combination group was higher than that in the contro1 group after treatment,the score of MH after treatment in the combination group was 1ower than that in the contro1 group after treatment,with significant difference (P<0.05). The 1eve1 of CD3,CD4 and CD4/CD8 after treatment in the combination group was higher than that before treatment and in the contro1 group after treatment,with significant difference (P<0.05). Conclusion Cinobufagin combined with TACE can significant1y improve immune ce11 function in primary HCC patients,enhance short-term effect and improve the qua1ity of 1ife.
贾金莹. 华蟾素联合经肝动脉化疗栓塞治疗原发性肝细胞癌的临床效果[J]. 中国当代医药, 2016, 23(8): 52-54转57.
JIA Jin-ying. Clinical effect of cinobufagin combined with transhepatic arterial chemotherapy and embolization in the treatment of primary hepatocellular carcinoma. 中国当代医药, 2016, 23(8): 52-54转57.